Thyrotropin-releasing hormone (TRH) analogues show enhanced CNS selectivity because of increased biological stability.
TRH exerts both endocrinological and neuropharmacological actions. Two analogues of TRH, Pyr-His-Mep . NH2 (L-trans-3-methylprolineamide) and Pyr-His-Dmp . NH2 (L-3,3-dimethylprolineamide) have been examined for their neuropharmacological and endocrinological effects. Comparisons of their ability to provoke hyperthermia in rabbits demonstrated that both analogues were more potent than TRH, but like the parent peptide had only a limited ability to cross the blood brain barrier. This conclusion was confirmed by whole body autoradiographical studies. In contrast both analogues had a similar potency to TRH with respect to the ability to provoke TSH release. It is concluded that the increased potency in neuropharmacological tests results from enhanced bioavailability to CNS sites and that a similar rationale can be used to explain the CNS selectively claimed in the literature for other analogues of TRH.
D000818:Animals; D001682:Biological Availability; D001812:Blood-Brain Barrier; D002490:Central Nervous System / Q000187:drug effects*; D005334:Fever / Q000139:chemically induced; D008297:Male; D010902:Pituitary Gland / Q000187:drug effects; D011761:Pyrrolidonecarboxylic Acid / Q000031:analogs & derivatives; D011817:Rabbits; D051381:Rats; D013972:Thyrotropin / Q000378:metabolism; D013973:Thyrotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology*
D013973:Thyrotropin-Releasing Hormone; C030668:pyroglutamyl-histidyl-3-methylprolinamide; C027979:L-pyroglutamyl-L-histidyl-3,3-dimethylprolinamide; D013972:Thyrotropin; D011761:Pyrrolidonecarboxylic Acid